Discovery of Novel Allosteric Non-Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthase by Integrated Lead Finding (Q27702178)

1

0 references

René Amstutz

2

0 references

Guido Bold

3

0 references

Emmanuelle Bourgier

4

0 references

Simona Cotesta

5

0 references

J Fraser Glickman

6

0 references

Marjo Götte

7

0 references

Christelle Henry

8

0 references

Sylvie Lehmann

9

0 references

J Constanze D Hartwieg

10

0 references

Silvio Ofner

11

0 references

Xavier Pellé

12

0 references

Jean-Michel Rondeau

14

0 references

Frédéric Stauffer

15

0 references

Steven J Stout

16

0 references

Armin Widmer

17

0 references

Johann Zimmermann

18

0 references

Thomas Zoller

19

0 references

Wolfgang Jahnke

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

20

0 references

publication date

November 2015

0 references

published in

ChemMedChem

0 references

volume

10

0 references

issue

11

0 references

page(s)

1884-91

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Biochemical and molecular mechanisms of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Recent advances in understanding the mechanism of action of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

The interferon-inducible protein viperin inhibits influenza virus release by perturbing lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Bisphosphonates as chemotherapeutic agents against trypanosomatid and apicomplexan parasites

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Lipophilic Bisphosphonates as Dual Farnesyl/Geranylgeranyl Diphosphate Synthase Inhibitors: An X-ray and NMR Investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Lipophilic pyridinium bisphosphonates: potent gammadelta T cell stimulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Design and synthesis of active site inhibitors of the human farnesyl pyrophosphate synthase: apoptosis and inhibition of ERK phosphorylation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Farnesyl diphosphate synthase inhibitors from in silico screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Structural characterization of substrate and inhibitor binding to farnesyl pyrophosphate synthase from Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Syntheses and characterization of non-bisphosphonate quinoline derivatives as new FPPS inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

A General Strategy for Targeting Drugs to Bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Farnesyl pyrophosphate synthase: real-time kinetics and inhibition by nitrogen-containing bisphosphonates in a scintillation assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

High-content assay to study protein prenylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Cardiotonic agents. 2. Synthesis and structure-activity relationships in a new class of 6-, 7-, and 8-pyridyl-2(1H)-quinolone derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

2-Alkynyl-8-aryladenines possessing an amide moiety: their synthesis and structure-activity relationships of effects on hepatic glucose production induced via agonism of the A(2B) adenosine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Antitumor effects of bisphosphonates: from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Antitumor Effects and Anticancer Applications of Bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

New role for an established drug? Bisphosphonates as potential anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Can we consider zoledronic acid a new antitumor agent? Recent evidence in clinical setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

Carboxylic acid (bio)isosteres in drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338

The most transformative drugs of the past 25 years: a survey of physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201500338